Zhejiang AngLiKang Pharmaceutical Competitors and Similar CompaniesClear all

Zhejiang AngLiKang Pharmaceutical's competitors and similar companies include Traphaco, Arinna Lifesciences, Gdziepolek and Alteus Biogenics.

	Zhejiang AngLiKang Pharmaceutical Zhejiang AngLiKang Pharmaceutical (AngLiKang) is a manufacturer, developer, and distributor of pharmaceuticals and medical products.	Traphaco Traphaco is a company that provides pharmaceuticals.	Arinna Lifesciences Arinna Lifesciences is a company that markets and develops pharmaceutical medicines.	Gdziepolek Gdziepolek (GdziePoLek) is a company that operates a chain of pharmacies that provides medicinal and healthcare products.	Alteus Biogenics Alteus Biogenics is a provider of medical and healthcare products.
Founding Date	Founding Date 1994	Founding Date 1972	Founding Date 2013	Founding Date 2014	Founding Date 2008
Type	Type Public	Type Public	Type Private	Type Private	Type Private
Tags	Tags Healthcare distribution drug development drug monitoring	Tags Healthcare distribution drug development drug monitoring	Tags Healthcare distribution drug development drug monitoring supplements	Tags Healthcare distribution drug development drug monitoring	Tags Healthcare distribution drug development drug monitoring pharmacy
Locations	Locations Shaoxing Shi, CN HQ	Locations VN HQ Singapore, SG	Locations Ahmedabad, IN HQ	Locations Warszawa, PL HQ	Locations Thane, IN HQ Kolkata, IN
Employees	Employees 1,290	Employees 55	Employees N/A	Employees 284% increase	Employees 4023% increase
Financial
Revenue (est.)	Revenue (est.) ¥1.4b (FY, 2025)	Revenue (est.) ₫2.7t (FY, 2025)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) N/A
Cost of goods	Cost of goods ¥862.4m (FY, 2025)	Cost of goods ₫1.2t (FY, 2025)	Cost of goods N/A	Cost of goods N/A	Cost of goods N/A
Gross profit	Gross profit ¥545.5m (FY, 2025)	Gross profit ₫1.5t (FY, 2025)	Gross profit N/A	Gross profit N/A	Gross profit N/A
Net income	Net income ¥156.7m (FY, 2025)	Net income ₫278.4b (FY, 2025)	Net income N/A	Net income N/A	Net income N/A